Policy for Science
POLITICO – The Trump administration is narrowing down candidates for a new post to coordinate the development of Covid-19 therapies and vaccines, with a former National Institutes of Health director emerging as a leading choice.
The Hill – It’s baffling therefore to see the EPA persisting with a 2018 proposed rule that weakens EPA’s scientific process and undermines its mission to protect the environment and the health of the US population.
Bloomberg Law – The FDA and NIH haven’t been able to recruit top scientists under an authority provided in the 21st Century Cures law because they’re still waiting for guidance on how many people they can hire.
The Conversation – Now, two months after implementing some form of physical distancing, European governments are planning to reopen their economies.
STAT – The federal government on Saturday announced a plan to distribute remdesivir following nearly a week of chaos and confusion surrounding which hospitals and which states would receive the medication, and how they were chosen.
STAT – At the heart of the decision about when to end the trial was a process that was — as is often in the case in clinical trials — by turns secretive and bureaucratic.
Washington Post — The exodus has been fueled broadly by administration policies that have diminished the role of science as well as more specific steps, such as the relocation of agencies away from the nation’s capital.
HealthITAnalytics — AMIA is calling for NIH to significantly change its data management and sharing policy so that it better leverages data and advances medical research.